[
  {
    "ts": null,
    "headline": "Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with...",
    "url": "https://finnhub.io/api/news?id=c0d4d9ef77aca618e4d5ed172d9d7c208235eb380d1a6e2a84094dc920a1ebb8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737817263,
      "headline": "Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 132470290,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with...",
      "url": "https://finnhub.io/api/news?id=c0d4d9ef77aca618e4d5ed172d9d7c208235eb380d1a6e2a84094dc920a1ebb8"
    }
  }
]